30 September 2025 : Original article
Post-Transplant Outcomes in Patients with Previously Treated Extrahepatic Malignancies Undergoing Living Donor Liver Transplantation
Amy Kim
BDEF 1, Shin Hwang ABCDEF 1*, Chul-Soo Ahn BDE 1, Deok-Bog Moon BCE 1, Tae-Yong Ha BCD 1, Gi-Won Song BCDF 1, Dong-Hwan Jung BCF 1, Gil-Chun Park BCD 1, Woo-Hyoung Kang BCD 1, Young-In Yoon BCD 1, Sung-Gyu Lee AEF 1
DOI: 10.12659/AOT.949461
Ann Transplant 2025; 30:e949461
Table 1 Baseline characteristics of patients treated for extrahepatic malignancy prior to living donor liver transplantation.
| n=109 | |
|---|---|
| Age at LT (years) | 57.2±8.5 |
| Sex (n) | |
| Male | 67 (61.5%) |
| Female | 42 (38.5%) |
| Primary liver disease (n) | |
| HBV infection | 64 (58.7%) |
| HCV infection | 7 (6.4%) |
| Alcoholic liver disease | 19 (17.4%) |
| Cryptogenic cirrhosis | 11 (10.1%) |
| Autoimmune hepatitis | 2 (1.8%) |
| Others | 6 (5.5%) |
| Concurrent hepatocellular carcinoma (n) | 49 (45.0%) |
| Within Milan criteria | 39 |
| Beyond Milan criteria | 10 |
| MELD score | 15.50±8.83 |
| Graft-to-recipient weight ratio | 1.16±0.31 |
| ABO-incompatible LT (n) | 20 (18.3%) |
| EHM diagnosis (n) | |
| Stomach cancer | 30 (27.5%) |
| Thyroid cancer | 12 (11.0%) |
| Breast cancer | 12 (11.0%) |
| Colorectal cancer | 11 (10.1%) |
| Kidney cancer | 11 (10.1%) |
| Lymphoma | 9 (8.3%) |
| Prostate cancer | 5 (4.6%) |
| Cervical cancer | 4 (3.7%) |
| Endometrial cancer | 2 (1.8%) |
| Lung cancer | 2 (1.8%) |
| Others | 11 (10.1%) |
| Interval between EHM treatment and LT (months) | 84.4±78.0 (range: 6–336) |
| Results reported as mean±SD or as n (%). LT – liver transplantation, HBV – hepatitis B virus; HCV – hepatitis C virus; MELD – model for end-stage liver disease; EHM – extrahepatic malignancy. | |